Advertisement

Specialty News

July 01, 2016
July 12, 2016
Tumor lysis syndrome (TLS), a potential complication of cancer treatment, occurs when malignant cells quickly lyse, or break open, and the internal...
Tumor lysis syndrome (TLS), a potential complication of cancer treatment, occurs when malignant cells quickly lyse, or break open, and the internal contents of the cell spill out into the bloodstream, causing metabolic abnormalities. Most often occurring 48–72 hours after the initiation of cancer treatment for hematologic malignancies, TLS may present before cancer therapy and occur with other tumor types, such as breast cancer, small cell lung cancer, and neuroblastoma.1-3
MORE
May 20, 2016
May 20, 2016
*
MORE
April 13, 2016
April 13, 2016
**
MORE
April 13, 2016
April 13, 2016
**
MORE
April 13, 2016
April 13, 2016
**
MORE
April 13, 2016
April 13, 2016
**
MORE
April 13, 2016
April 13, 2016
**
MORE
January 13, 2016
January 13, 2016
The new year started with one FDA-approved biosimilar drug on the market and at least five others in the pipeline. The newcomers represent an...
Biosimilars Primer
MORE

Pages